Norepinephrine

Atomoxetine

Atomoxetine is a selective norepinephrine reuptake inhibitor used to treat attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. Unlike stimulant ADHD medications, it is not a controlled substance and carries essentially no potential for misuse, since it does not produce euphoria. Developed by Eli Lilly and approved in the United States in 2002 under the brand name Strattera, it works by blocking the norepinephrine transporter and is usually considered a second-line option after stimulants.

L-Tyrosine

L-Tyrosine is an aromatic amino acid used to build proteins and to make several important signaling molecules. Because the body can produce it from the essential amino acid phenylalanine, it is usually classed as non-essential, or conditionally essential when phenylalanine is scarce. It is the raw material for the catecholamine neurotransmitters dopamine, norepinephrine, and epinephrine, as well as for thyroid hormones and the pigment melanin, and it is sold as a supplement studied mainly for mental performance under stress.

Phenylalanine

Phenylalanine is an essential amino acid and the first step in making dopamine and noradrenaline: the body converts it to tyrosine, tyrosine to L-DOPA, and L-DOPA to dopamine. That chain is the entire basis for taking it, and it is also the reason to be measured about it, because supplying more of the first ingredient does not reliably speed up a pathway that is regulated further downstream. The best-supported use is not mood at all; L-phenylalanine combined with light therapy has a real if modest evidence base in vitiligo [9][10]. The critical safety fact is short and absolute: anyone with phenylketonuria must not take it [7].

PPAP

PPAP is a laboratory compound derived from selegiline that was designed to stimulate the brain without the uncontrolled neurotransmitter dumping that amphetamines cause. In rats it increases the dopamine and noradrenaline released when a nerve cell actually fires, an effect its developers named a catecholaminergic activity enhancer effect; unlike selegiline it does not block the enzyme MAO-B. A 2026 screening study also found it blocks dopamine reuptake, slightly more strongly than amphetamine did in the same assay. Almost the entire evidence base is rat and cell work from one Hungarian laboratory; PPAP has never been given to a human in any published study, so no human dose or safety information exists, and it has since appeared as an unregulated substance on the European drug market.

BPAP

BPAP is an experimental laboratory compound created in the late 1990s by the Hungarian and Japanese team behind selegiline; it has never been approved as a medicine in any country. It is described as a "monoaminergic activity enhancer", meaning that in animal tissue it makes dopamine, noradrenaline and serotonin neurons release more transmitter when they fire, rather than forcing transmitter out the way amphetamine does; at higher concentrations it also blocks dopamine and noradrenaline reuptake. Essentially all the evidence comes from rats, mice and cell cultures, and almost all of it was produced by the two groups with a stake in the compound, namely Knoll's Semmelweis University laboratory and Fujimoto Pharmaceutical Corporation. No clinical trial in humans has ever been run or even registered, so claims about memory, mood, longevity or anti-aging benefit in people rest on no human evidence at all.

Tesofensine

Tesofensine is a triple monoamine reuptake inhibitor, originally investigated for Parkinson's and Alzheimer's disease, that produced some of the largest weight losses reported for an appetite-suppressing drug. By simultaneously blocking the reuptake of dopamine, noradrenaline, and serotonin it curbs hunger and increases satiety, and it additionally silences appetite-driving GABAergic neurons in the hypothalamus. In a phase 2 obesity trial it produced weight loss roughly twice that of the obesity medications approved at the time, though that trial has carried an expression of concern over its adverse-effect reporting since 2013; it remains investigational, with cardiovascular effects among the safety considerations.

Beta-Blocker

Propranolol

Propranolol is a nonselective beta-adrenergic receptor antagonist, one of the first drugs of its kind and a mainstay of cardiovascular medicine. Developed by the British scientist James Black in the early 1960s, it blocks the actions of adrenaline and noradrenaline at both beta-1 and beta-2 receptors and is used for conditions ranging from hypertension, angina, and irregular heart rhythms to migraine prevention, essential tremor, and performance anxiety. It also became the first effective drug treatment for infantile hemangioma. Propranolol appears on the World Health Organization list of essential medicines and is available only by prescription.

RGPU-95

RGPU-95 is an experimental compound studied in Russian pharmacological research as a structural analog of fenotropil, better known as phenylpiracetam, a nootropic of the racetam family. In animal experiments it has shown anxiety-reducing and antidepressant-like effects, in some measures exceeding those of its parent compound. It is an obscure investigational substance with essentially no human data, and it is not an approved medicine or recognized supplement ingredient anywhere.

1,3-DMAA

1,3-DMAA (1,3-dimethylamylamine, methylhexanamine) is a potent aliphatic amine stimulant that defined the golden era of hardcore pre-workouts, prized for driving energy, appetite suppression, and razor focus. Originally patented in the 1940s as a nasal decongestant, it delivers an amphetamine-adjacent lift through indirect adrenergic stimulation and a distinctive vasoconstrictive edge. Its reputation as one of the most intense stimulants ever sold in sports nutrition kept demand high even as regulators moved to restrict it.

1,4-DMAA

1,4-DMAA (1,4-dimethylamylamine) is an experimental aliphatic amine stimulant that emerged as a next-generation successor to the banned 1,3-DMAA, marketed for the same hard-hitting pre-workout energy and focus. As a positional isomer of the classic DMAA molecule, it gives formulators a structurally distinct route to intense adrenergic stimulation. It remains a rare, sought-after ingredient in a handful of underground sports and weight-loss products, appealing to enthusiasts chasing the original DMAA experience.

Bupropion

Bupropion is an atypical antidepressant of the aminoketone class that works mainly as a norepinephrine-dopamine reuptake inhibitor. It is used to treat major depressive disorder and seasonal affective disorder and, under a separate brand, as an aid to quitting smoking; it is also part of a combination weight-loss product. Unlike many antidepressants it has little direct effect on serotonin and rarely causes sexual dysfunction or weight gain.

Supplement

Carnosic Acid

Carnosic acid is a phenolic diterpene found in the herbs rosemary (Salvia rosmarinus) and common sage (Salvia officinalis), where it is one of the main compounds responsible for their antioxidant activity. Together with its oxidation product carnosol, it is used commercially as a natural antioxidant food preservative, labeled as rosemary extract (E392). It has been studied extensively for antioxidant, anti-inflammatory, and neuroprotective effects, which are largely attributed to its ability to activate the cell's Nrf2 defense pathway.

Clomipramine

Clomipramine is a tricyclic antidepressant (TCA), sold chiefly under the brand name Anafranil, best known as one of the most effective drug treatments for obsessive-compulsive disorder [1][2]. It also treats major depression, panic disorder and cataplexy, and is used off-label for conditions such as premature ejaculation and chronic pain [1][2]. Introduced by the Swiss firm Geigy in the 1960s as a chlorinated relative of imipramine, it is the most strongly serotonergic of the older tricyclics and appears on the World Health Organization's list of essential medicines [1][2].

Guarana

Guarana is a climbing plant native to the Amazon basin, classified as Paullinia cupana in the soapberry family Sapindaceae, whose seeds are prized for an unusually high caffeine content. Indigenous peoples of the region, including the Sateré-Mawé, have long processed the seeds into a dried paste used to brew a stimulating beverage. Today the seed powder and its extracts are used chiefly as a caffeine source in soft drinks, energy drinks, and dietary supplements.

N-Acetyl L-Tyrosine (NALT)

N-Acetyl L-Tyrosine (NALT) is an acetylated, more water-soluble form of the amino acid L-tyrosine, originally introduced as a tyrosine source for intravenous nutrition. It is widely marketed as a nootropic on the premise that tyrosine is the precursor of the catecholamine neurotransmitters dopamine and norepinephrine. However, human and animal studies indicate that N-Acetyl L-Tyrosine is converted to free tyrosine inefficiently, with much of an infused dose excreted unchanged in the urine.

Nicergoline

nicergoline (sermion) is a semisynthetic ergoline nootropic-vasodilator; a potent alpha-1 blocker that also boosts cholinergic/neurotrophic tone, with modest but real cochrane-backed benefit in age-related and vascular cognitive decline, tempered by ergot-class fibrosis risk on long timelines.

Nortriptyline

Nortriptyline is a secondary-amine tricyclic antidepressant and the active metabolite of amitriptyline, distinguished among tricyclics by its relative selectivity for norepinephrine reuptake inhibition over serotonin. It is notable for a well-defined curvilinear therapeutic plasma window, an early landmark in therapeutic drug monitoring, and it is generally better tolerated than tertiary-amine tricyclics in older patients. Beyond depression, it is widely used off-label for neuropathic pain and migraine prophylaxis, effects attributed partly to blockade of voltage-gated sodium channels that also underlies its local-anesthetic activity and, in overdose, its cardiotoxicity. It has additionally demonstrated efficacy as an aid to smoking cessation. Approved in the United States in 1964, it remains an inexpensive generic.

Tranylcypromine

Tranylcypromine is an antidepressant of the monoamine oxidase inhibitor (MAOI) class, used mainly for major depression that has not responded to other treatments [1][2]. It works by irreversibly blocking monoamine oxidase, the enzyme that breaks down mood-related neurotransmitters, and it is chemically related to amphetamine [1]. Introduced around 1960 and sold under the brand name Parnate, it requires a tyramine-restricted diet because of the risk of dangerous blood pressure spikes.

Yohimbine

Yohimbine is an indole alkaloid obtained mainly from the bark of the West African tree Pausinystalia johimbe (yohimbe). Pharmacologically it acts chiefly as an antagonist of alpha-2 adrenergic receptors, and it has a long history as a purported aphrodisiac and a treatment for erectile dysfunction. It is available in some countries as a prescription drug and elsewhere as a dietary supplement, though its stimulant-like cardiovascular effects and inconsistent product quality have raised safety concerns.

Amitriptyline

Amitriptyline is a tricyclic antidepressant introduced in the early 1960s, originally for major depression and now used at least as often for chronic pain conditions. It relieves symptoms by increasing the availability of the neurotransmitters serotonin and norepinephrine, while also blocking histamine, acetylcholine, and adrenergic receptors, which accounts for both its sedating quality and many of its side effects [1]. Common uses today include neuropathic pain, fibromyalgia, and the prevention of migraine and tension headaches, in addition to depression [3][4].

Duloxetine

Duloxetine is a balanced serotonin-norepinephrine reuptake inhibitor, marketed chiefly as Cymbalta since 2004, approved for major depression and generalized anxiety as well as several chronic pain conditions. Its analgesic action reflects potentiation of descending serotonergic and noradrenergic pathways that dampen pain signaling in the spinal cord, an effect largely separate from its antidepressant activity. Randomized trials support its use in diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain from osteoarthritis and low back pain, and it is the agent with the strongest randomized evidence recommended by oncology guidelines for chemotherapy-induced peripheral neuropathy. Through the same monoaminergic facilitation of pudendal motor neurons in Onuf's nucleus, duloxetine strengthens urethral sphincter tone and is used in some countries for stress urinary incontinence. It is a prescription-only medicine, available generically, and appears on the World Health Organization list of essential medicines.

Anxiolytic

Flibanserin

Flibanserin is a serotonergic medication approved to treat hypoactive sexual desire disorder (HSDD) in premenopausal women, sold under the brand name Addyi. It was first developed as an antidepressant but was repurposed after it appeared to influence sexual desire. Unlike drugs for erectile dysfunction, it is taken daily and acts on the brain rather than on blood flow. Its 2015 approval by the United States Food and Drug Administration was controversial, following two earlier rejections and a debate over whether its modest benefits justified its risks.

Mirtazapine

Mirtazapine is a tetracyclic antidepressant, often classified as a noradrenergic and specific serotonergic antidepressant (NaSSA), used primarily to treat major depressive disorder. Rather than blocking the reuptake of neurotransmitters like most modern antidepressants, it works by blocking a set of receptors, which increases noradrenaline and serotonin signaling and produces marked sedative and appetite-stimulating effects. Introduced in the 1990s and sold under brand names such as Remeron, it is a prescription medicine available as a generic.

Clenbuterol

Clenbuterol is used for fat loss, and that is the only reason most people encounter it, so it is worth being direct about what the evidence supports. It is a long-acting beta-2 agonist licensed in some countries as an asthma bronchodilator and widely used in veterinary medicine; it raises metabolic rate and drives lipolysis, and in livestock and rodents it reliably shifts body composition toward lean mass [32][31]. What is missing is the human version of that result. There is no controlled trial showing clenbuterol produces meaningful fat loss in healthy people, while there is a systematic review of case reports documenting what it does produce: tachycardia, arrhythmia, myocarditis and hospital admissions [14]. The gap between those two literatures is the whole story.

3 outlets